Historical Archive

International meeting of ISF Associations

Since 2000, the big pharmaceutical companies have been waving the bogeyman of the crisis. Research crisis for which, they argue, funds are gradually running out.

Two scholars, after an article in the British Medical Journal, have instead accused the pharmaceutical companies, which would have actually created the false myth of the research crisis to obtain greater concessions from the member states.

The scarcity of funds available for research is not in fact the result of the crisis, but of very specific company policies, which invest in research to an extent of 1 to 19 compared to what they invest in marketing campaigns, the promotion of which can even represent the ' 80% of a nation's pharmaceutical expenditure.

In fact, the scientists explain that companies actually invest in minor projects, i.e. in variations of existing drugs which, with well-supported marketing campaigns, bring more profit to pharmaceutical companies but which, in fact, do not offer any type of solution clinic that does not already exist on the market.

A bluff, this, which is abundantly financed by the various individual states which, however, in exchange for heavy pharmaceutical costs have actually obtained drugs which, in 85,90% of the cases, bring very few benefits and, on the other hand, bring considerable benefits. harm to public health.

The voices are different and come from different and independent groups of scientists, who have verified that the number of new drugs produced in a year, from 2000 to today, ranges from 15 to 25 new drugs a year, which however again often very little.

According to experts, the correction of this system must be political: a brake on the continuous approval of new drugs that have very little therapeutic value could be the only way to ensure that pharmaceutical companies really invest in research and not above all in marketing campaigns .

European states spend billions in healthcare spending, billions which instead of being converted into the search for new therapeutic solutions are converted into drug marketing campaigns for 80% which again in reality have absolutely nothing.

Morena Lolli
February 16, 2013 – StSCIENCES-NoATURAL

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco